Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2021

View Archived Issues

Enrollment open in phase I/II study of TP-102 bacteriophage therapy in diabetic foot ulcers

Qpex Biopharma initiates phase I study of QPX-7831

Inactivation of p62 reduces skin lesions in an atopic dermatitis-like mouse model

Personalized Stem Cells reports data from phase I/IIa trial of cell therapy for knee osteoarthritis

PXS-6302 enters first-in-human study for prevention of wound and burn scars

ChAdOx1 nCoV-19 vaccine does not protect against B.1.351 variant in South Africa trial

Daiichi Sankyo launches phase I study of DS-2319 for COVID-19

First volunteer dosed in phase I study of ALS-4 as treatment of MRSA

Dosing begins in phase Ib study of FX-301 for management of postoperative pain

Topline data from phase IIb portion of the phase IIb/III COVID-19 trial of ifenprodil

First patient dosed in registrational phase I/II study of GC-007G

5-HT4 receptor agonists discovered at Sunshine Lake Pharma

Amgen describes new IL-22 compositions

IMPACT Therapeutics identifies new ATM kinase inhibitors

New Nur77 receptor ligands disclosed by Ixmedicine

Sichuan Kelun-Biotech Biopharmaceutical patents nuclear receptor ROR-gamma agonists

COMMD1 as therapeutic target and diagnostic biomarker in NSCLC

Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms

Qinlock approved in China for advanced GIST

China's NMPA approves Ayvakit for GIST with PDGFRA exon 18 mutation

Yingli reports phase II topline data on linperlisib in relapsed or refractory follicular lymphoma

U.S. approval for Sarclisa with Kd for relapsed or refractory multiple myeloma

Celon reports phase I data on second-generation GPR40 agonist CPL-280

FDA approves Roszet to treat elevated LDL-C in primary nonfamilial hyperlipidemia and HoFH

Tsukushi protein mutations can lead to hydrocephalus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...